Emtricitabine

Emtricitabine (CAS 143491-57-0), also known by the development codes BW-524W91 and 524W91 and abbreviated as FTC, is a synthetic nucleoside analogue used as an active pharmaceutical ingredient in antiviral therapy. It functions as a reverse transcriptase inhibitor, blocking viral replication in HIV and hepatitis B treatment regimens. FTC is the primary API in several approved fixed-dose combination antiretroviral tablets.

In these formulations, it is co-formulated with tenofovir, efavirenz, or integrase inhibitors for once-daily HIV treatment. It is also incorporated into pre-exposure prophylaxis formulations targeting HIV prevention. Pharmaceutical manufacturers source this material as a key intermediate for producing both branded and generic antiretroviral drug products. Research organizations and contract development manufacturers procure it for development.

It is frequently used for bioequivalence studies and analytical reference standard preparation. Emtricitabine is supplied as a white to off-white crystalline powder for various industrial applications. It is available in pharmaceutical-grade quality aligned with USP and Ph. Eur. monograph specifications, supporting both clinical and commercial manufacturing requirements for global distribution.

Bulk API quantities and smaller research-grade lots are both available depending on the procurement stage. This ensures flexibility for laboratories and large-scale pharmaceutical production facilities alike.